Milestone Scientific Highlights Operational Progress and Growth Initiatives Under New Leadership

Rhea-AI Summary

Milestone Scientific (NYSE American: MLSS) provided a business update dated October 14, 2025 outlining operational changes under new CEO Eric Hines, who joined two months earlier. Management reported a ~20% reduction in operating expenses in Q3 2025 versus Q3 2024, modest revenue growth, and an uptick in recurring revenue from CompuFlo disposables. The company plans to expand North American dental sales, strengthen direct-sales and omnichannel marketing for the STA® Single Tooth Anesthesia system, pursue new international registrations, and execute a guided relaunch and reimbursement strategy for CompuFlo in medical markets. Broad-based cost reductions and investments in market analysis aim to position the company for accelerated growth and improved financial performance.

Positive

• Operating expenses reduced by ~20% in Q3 2025 vs Q3 2024
• Reported modest revenue growth alongside expense reductions
• Noted uptick in recurring revenue from CompuFlo disposables
• Plans for expanded North American dental sales and direct-sales focus

Negative

• None.

Insights

Corporate transformation analyst

Management outlines cost cuts, sales relaunches, and early revenue signs under new CEO; initiatives are execution‑dependent.

Management has implemented a clear operational reset across the dental and medical segments, focusing on expanded North American direct sales, omnichannel marketing, new international registrations for the STA® system, and a guided relaunch of CompuFlo®. The company reports a ~20% reduction in operating expenses in Q3 versus the prior year period, concurrent with modest revenue growth and higher recurring revenue from CompuFlo disposables; these are concrete, near‑term efficiency and revenue signals.

Execution risk remains the primary dependency: the stated benefits rely on scaling direct sales, successful international regulatory registrations, effective reimbursement strategies, and the relaunch traction for CompuFlo. Cost cuts alone do not guarantee durable profit improvement if revenue growth lags or if investments in sales and marketing are insufficient.

Watch for measurable milestones over the next 3–12 months: published quarterly revenue and margin trends, confirmation of new international registrations and their timing, early CompuFlo adoption metrics and reimbursement pathways, and whether operating expense reductions persist or are offset by reinvestment. These items will determine whether the operational changes translate into sustainable financial improvement.

Company outlines decisive initiatives to strengthen its dental and medical businesses, reduce operating expenses across the organization, and position Milestone Scientific for accelerated growth and improved financial performance

ROSELAND, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE American: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update highlighting the Company’s transformation and growth initiatives under the leadership of its new Chief Executive Officer, Eric Hines.

Since joining Milestone Scientific two months ago, Mr. Hines has conducted a comprehensive review of the Company’s operations and implemented a series of strategic actions designed to accelerate growth, strengthen its competitive position, and improve operating efficiency. Actions within the dental segment include expanding the Company’s North American sales programs and increasing the focus on direct sales opportunities; streamlining and expanding omnichannel digital marketing to increase brand awareness; and securing new international registrations for the STA® Single Tooth Anesthesia System. The Company plans to utilize a similar strategy for its medical segment, including a guided relaunch of CompuFlo®. In addition, the Company is investing in specialized market analysis and reimbursement strategies to maximize the commercial potential of the Company’s CompuFlo® technology in healthcare settings. Lastly, the Company is instituting broad-based reductions in operating expenses across the organization.

“We have taken strong, decisive steps over the past two months to align Milestone Scientific for the next phase of growth,” stated Eric Hines, Chief Executive Officer of Milestone Scientific. “Through a top-to-bottom analysis of the business, we have identified significant opportunities for improvement and begun executing initiatives to capture them. Notably, during the third quarter, we reduced our operating expenses by approximately 20% compared to the same period in 2024, while achieving modest revenue growth and seeing an uptick in recurring revenue from the CompuFlo disposables, even before fully implementing our new sales and marketing initiatives. We are also observing strong interest in CompuFlo internationally. Although we have been relatively quiet publicly, there is a significant amount of activity taking place behind the scenes that we believe will strengthen both our medical and dental segments and enhance the Company’s financial performance.”

Hines continued, “We remain committed to advancing our innovative technology, expanding our market presence, and executing on our pipeline of new products and partnerships. The steps we are taking now – from strengthening our sales infrastructure to optimizing our operations – provide a strong foundation for sustained growth and profitability.   I could not be more encouraged by the outlook for the business and look forward to sharing updates on our progress.”

About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS) is a technology-focused medical research and development company that patents, designs, and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient, and increase the overall patient comfort and safety. The Company leverages its proprietary DPS Dynamic Pressure Sensing Technology^® platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetics. To learn more, view the MLSS brand video or visit milestonescientific.com.

Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contact:         
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020

FAQ

What did Milestone Scientific (MLSS) announce on October 14, 2025 about leadership?

Milestone named Eric Hines as CEO; he joined two months earlier and initiated a company-wide review.

How much did Milestone Scientific (MLSS) cut operating expenses in Q3 2025?

The company reported operating expenses were reduced by about 20% in Q3 2025 versus Q3 2024.

What commercial actions is Milestone Scientific (MLSS) taking for STA and CompuFlo?

Plans include expanded North American dental sales, omnichannel marketing for STA, and a guided relaunch plus reimbursement strategy for CompuFlo.

Did Milestone Scientific (MLSS) report revenue changes in the update?

Yes; management said it achieved modest revenue growth and an uptick in recurring CompuFlo disposable revenue.

Is Milestone Scientific (MLSS) expanding internationally for its products?

Yes; the company is securing new international registrations and reported growing international interest in CompuFlo.

What is Milestone Scientific (MLSS) doing to improve financial performance?

The company is reducing operating expenses, investing in market analysis and reimbursement strategies, and strengthening sales and marketing.